Cladribine and Profen drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cladribine (cladribine) and Profen (ibuprofen). Common drug interactions include erythema among females and constipation among males.

The phase IV clinical study analyzes what interactions people have when they take Cladribine and Profen. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Cladribine?

Cladribine has active ingredients of cladribine. eHealthMe is studying from 2,540 Cladribine users. Check the latest studies of Cladribine.

What is Profen?

Profen has active ingredients of ibuprofen. It is often used in pain. eHealthMe is studying from 245,311 Profen users. Check the latest studies of Profen.



On Jul, 16, 2026

35 people who take Cladribine and Profen together, and have interactions are studied.

Cladribine and Profen drug interactions.

What are the common drug interactions of Cladribine and Profen, by gender? *:

female:

  1. Erythema (redness of the skin)
  2. Red blood cell sedimentation rate increased
  3. Depressed mood
  4. Dyspnoea (difficult or laboured respiration)
  5. Acne (skin problems that cause pimples)
  6. Alopecia (absence of hair from areas of the body)
  7. Angular cheilitis (inflammation of one, or more commonly both, of the corners of the mouth)
  8. Aphasia (damage to the parts of the brain that control language)
  9. Asthenia (weakness)
  10. Blood oestrogen increased

male:

  1. Constipation
  2. Rhinitis allergic (inflammation of the nasal airways due to allergy)
  3. Teething (process by which an infant's first teeth grows)
  4. Drug ineffective
  5. Myalgia (muscle pain)
  6. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  7. Hypersensitivity
  8. Drug dependence
  9. Drug intolerance (drug sensitivity)
  10. Gingival pain (gum pain)

What are the common drug interactions of Cladribine and Profen, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Gingival pain (gum pain)
  2. Toothache (tooth pain)
  3. Myalgia (muscle pain)
  4. Erythema (redness of the skin)
  5. Therapeutic response decreased (less preventive response)
  6. Anaphylactic reaction (serious allergic reaction)
  7. Teething (process by which an infant's first teeth grows)
  8. Red blood cell sedimentation rate increased
  9. Drug ineffective
  10. Acne (skin problems that cause pimples)

50-59:

  1. Lymphopenia (an abnormally low level of lymphocytes in the blood)
  2. Kidney infection
  3. Lymphocyte count decreased
  4. Radius fracture

60+:

n/a

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 16 people, 45.71%
  2. Systemic Mastocytosis (a condition caused by the accumulation of mast cells in more than one part of the body): 14 people, 40.00%
  3. Joint Pain: 14 people, 40.00%
  4. Exostosis (formation of new bone on the surface of a bone): 9 people, 25.71%
  5. Bone Pain: 9 people, 25.71%
  6. Acne (skin problems that cause pimples): 9 people, 25.71%
  7. Urticaria Pigmentosa (skin disease that produces patches of darker skin (lesions) and very bad itching): 5 people, 14.29%
  8. Oesophageal Pain: 3 people, 8.57%
  9. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 8.57%
  10. Restless Leg Syndrome (a powerful urge to move your legs): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Cladribine and Profen?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cladribine and Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cladribine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Profen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cladribine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Profen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on cladribine and ibuprofen (the active ingredients of Cladribine and Profen, respectively), and Cladribine and Profen (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: